Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of PF-04965842 Solid Dose vs Suspension and Food Effect
NCT02163161Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abrocitinib in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve from Time Zero to infinity at 15 days, Maximum Observed Plasma Concentration at 15 days and 1 more. Started Jun 2014; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02163161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02163161.